MARKET

FOLD

FOLD

Amicus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.56
+0.57
+6.34%
After Hours: 9.56 0 0.00% 16:53 01/24 EST
OPEN
8.83
PREV CLOSE
8.99
HIGH
9.62
LOW
8.78
VOLUME
3.45M
TURNOVER
--
52 WEEK HIGH
21.34
52 WEEK LOW
8.41
MARKET CAP
2.66B
P/E (TTM)
-10.5975
1D
5D
1M
3M
1Y
5Y
Clearside Biomedical, Ebix lead postmarket gainers; Perella Weinberg Partners among losers
Gainers: Clearside Biomedical (NASDAQ:CLSD) +13%, Ebix (NASDAQ:EBIX) +7%, Cipher Mining (NASDAQ:CIFR) +6%, Array Technologies (NASDAQ:ARRY) +5%, Amicus Therapeutics (NASDAQ:FOLD) +4%. Losers: Perella Weinberg Partners -10%, ShockWave Medical (NASDAQ:SWAV) ...
Seekingalpha · 01/13 22:22
Amicus Therapeutics (FOLD) Stock Jumps 6.4%: Will It Continue to Soar?
Amicus Therapeutics (FOLD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks · 01/13 07:26
60 Biggest Movers From Yesterday
Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares surged 57.1% to close at $5.39 on Monday.
Benzinga · 01/11 09:52
Hot Stocks: ZNGA jumps on merger deal; DELL sets high; Consumer IPOs drop; FOLD plunges; TMUS hits low
Stocks bounced back from an early slide Monday, finishing with a mixed performance -- an attempt to stabilize after the losses posted over the previous several days. Concerns about higher
Seekingalpha · 01/10 23:03
Mid-Afternoon Market Update: Dow Tumbles 250 Points; Zynga Shares Spike Higher
Toward the end of trading Monday, the Dow traded down 0.70% to 35,978 while the NASDAQ fell 0.93% to 14,796.51. The S&P also fell, dropping, 0.72% to 4,643.29.
Benzinga · 01/10 19:30
MRIN, NRIX and ELYM among mid-day movers
Gainers: Bone Biologics (OTCPK:BBLG) +82%. Zynga (NASDAQ:ZNGA) +43%. RxSight (NASDAQ:RXST) +34%. Olink (NASDAQ:OLK) +31%. Apria (NASDAQ:APR) +26%. Molecular (NASDAQ:MOLN) +25%. iRhythm Technologies (NASDAQ:IRTC) +25%. BioCryst (NASDAQ:BCRX) +21%. G Medical...
Seekingalpha · 01/10 17:44
Mid-Day Market Update: Nasdaq Dips 300 Points; Apria Shares Surge
Midway through trading Monday, the Dow traded down 1.23% to 35,787.07 while the NASDAQ fell 2.07% to 14,627.21. The S&P also fell, dropping, 1.52% to 4,605.95.
Benzinga · 01/10 17:26
45 Stocks Moving In Monday's Mid-Day Session
Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares climbed 71.5% to $5.88.
Benzinga · 01/10 17:14
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FOLD. Analyze the recent business situations of Amicus through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

36.36%Strong Buy
36.36%Buy
27.27%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average FOLD stock price target is 17.33 with a high estimate of 29.00 and a low estimate of 14.00.
High29.00
Average17.33
Low14.00
Current 9.56
EPS
Actual
Estimate
-0.22-0.16-0.11-0.05
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 342
Institutional Holdings: 340.11M
% Owned: 122.06%
Shares Outstanding: 278.64M
TypeInstitutionsShares
Increased
83
32.35M
New
30
2.72M
Decreased
74
8.44M
Sold Out
25
8.60M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.12%
Pharmaceuticals & Medical Research
-0.55%
Key Executives
Chairman/Chief Executive Officer/Director
John Crowley
President/Chief Operating Officer/Director
Bradley Campbell
Chief Financial Officer
Daphne Quimi
Chief Accounting Officer/Vice President - Finance/Controller
Samantha Prout
Other
David Clark
Secretary
Ellen Rosenberg
Lead Director/Independent Director
Michael Raab
Independent Director
Lynn Bleil
Independent Director
Robert Essner
Independent Director
Michael Kelly
Independent Director
Margaret Mcglynn
Independent Director
Eiry Roberts
Independent Director
Glenn Sblendorio
Independent Director
Craig Wheeler
Independent Director
Burke Whitman
No Data
  • All
  • Financials
  • Insiders
More
About FOLD
Amicus Therapeutics, Inc. is a global biotechnology company that is focused on discovering, developing, and delivering medicines for rare diseases. The Company’s portfolio is Galafold (migalastat), which is the approved oral precision medicine for people living with Fabry disease. Migalastat is approved under the trade name Galafold in the United States, European Union, United Kingdom and Japan. Its biologics program in its pipeline is Amicus Therapeutics GAA (AT-GAA), which is a clinical-stage treatment paradigm for Pompe disease. The United States Food and Drug Administration (FDA) granted Breakthrough Therapy designation (BTD) to AT-GAA for the treatment of late onset Pompe disease. Its pipeline includes gene therapy programs in rare, neurologic lysosomal disorders (LDs), specifically: CLN6, CLN3 and CLN1 Batten disease, Pompe disease, Fabry disease, CDKL5 deficiency disorder (CDD), Mucopolysaccharidosis Type IIIB (MPS IIIB), as well as in Mucopolysaccharidosis Type IIIA (MPS IIIA).

Webull offers kinds of Amicus Therapeutics, Inc. stock information, including NASDAQ:FOLD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FOLD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FOLD stock methods without spending real money on the virtual paper trading platform.